Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics Platform.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

The New England journal of medicine·2026
Same author

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The immunology of vitiligo.

Nature reviews. Immunology·2026
Same author

Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E).

Oncogenesis·2025

相关实验视频

Updated: Jun 14, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

免疫检查站封锁:时间是一切.

Frank A Sinicrope1, Mary Jo Turk2

  • 1Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA Sinicrope.Frank@mayo.edu.

Journal for immunotherapy of cancer
|August 29, 2024
PubMed
概括

新辅助免疫疗法利用瘤来建立对癌症的全身免疫力. 治疗后手术切除瘤可能会阻碍这一关键的抗瘤反应,可能会影响患者的治疗结果.

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 癌症研究 癌症研究

背景情况:

  • 新辅助免疫疗法利用瘤微环境来刺激系统性抗瘤免疫力.
  • 瘤内的T细胞是对免疫检查点抑制剂 (ICI) 反应的关键媒介.
  • ICI主要是CD8+T细胞,通过阻断抑制检查点来增强抗瘤反应.

研究的目的:

  • 评估新辅助免疫治疗对瘤内和全身抗瘤免疫力的影响.
  • 评估内T细胞克隆扩张与病态治疗反应之间的关联.
  • 为了研究手术切除在新辅助ICI治疗后对抗瘤免疫力的潜在后果.

主要方法:

  • 对新辅助免疫治疗的内免疫反应的分析.
  • 评估T细胞在瘤中的原始化和淋巴结排水.
  • 病理性治疗反应与T细胞克隆扩张的相关性.
  • 在黑色素瘤患者中,新辅助剂与辅助剂ICI治疗结果的比较.

主要成果:

  • 新辅助性ICI治疗增强了内和全身抗瘤免疫力.
  • 内T细胞克隆的扩张与病态治疗反应有很强的相关性.
  • 新辅助免疫疗法显示出高病理反应率和晚期黑色素瘤的延长存活率.
关键词:
免疫检查点抑制剂 免疫检查点抑制剂免疫治疗是一种免疫疗法.新辅助剂是一种新辅助剂.一个T细胞细胞.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.5K

相关实验视频

Last Updated: Jun 14, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.5K
  • 辅助性ICI治疗单独可能比新辅助方法效果较差.

    • 结论:

    • 新辅助免疫疗法通过利用瘤作为抗原来源,有效地启动免疫系统对抗癌症.
    • 在新辅助疗法后的瘤外科切除可能会消除关键的瘤特异性T细胞,可能会损害长期的抗瘤免疫力和治疗疗效.